Introduction
============

There is increasing evidence that bisphenol A (BPA)---used in plastics, receipts, food packaging, and other products---might be harmful to human health due to its actions as an endocrine-disrupting chemical (EDC) ([@r5]; [@r53]; [@r54]). Scientists, regulators, and the general public have raised concerns about the use of BPA, especially because of its ubiquitous nature and potential for continuous exposure ([@r66]). This has prompted industry to seek alternative chemicals. As manufacturers have begun to remove BPA from their products as a result of consumer concern, there has been a gradual shift to using bisphenol analogs. For the purpose of our review, we chose to evaluate two of these analogs---bisphenol S (BPS) and bisphenol F (BPF)---because of their widespread consumer and commercial use. BPS is used for a variety of industrial applications, for example, as a wash fastening agent in cleaning products, an electroplating solvent, and a constituent of phenolic resin ([@r10]). BPS is also used as a developer in thermal paper, including products marketed as "BPA-free paper" ([@r36]). BPF is used to make epoxy resins and coatings, especially for systems needing increased thickness and durability (i.e., high-solid/high-build systems), such as tank and pipe linings, industrial floors, road and bridge deck toppings, structural adhesives, grouts, coatings, and electrical varnishes ([@r16]). BPF epoxy resins are also used for several consumer products such as lacquers, varnishes, liners, adhesives, plastics, water pipes, dental sealants, and food packaging ([@r45]). BPS and BPF have been detected in many everyday products, such as personal care products (e.g., body wash, hair care products, makeup, lotions, toothpaste) ([@r33]), paper products (e.g., currency, flyers, tickets, mailing envelopes, airplane boarding passes) ([@r36]), and food (e.g., dairy products, meat and meat products, vegetables, canned foods, cereals) ([@r32]). BPS, BPF, and BPA have been detected in indoor dust at the following concentrations: BPS, 0.34 μg/g; BPF, 0.054 μg/g; BPA, 1.33 μg/g ([@r35]). BPS and BPF have also been detected in surface water, sediment, and sewage effluent, generally at lower concentrations than BPA, but in the same order of magnitude ([@r18]; [@r60]; [@r77]). In humans, BPS and BPF have been detected in urine at concentrations and frequencies comparable to BPA ([@r34]; [@r79]). In urine samples from 100 American, nonoccupationally exposed adults, [@r34] found BPF in 55% of samples at concentrations up to 212 ng/mL, and BPS in 78% of samples at concentrations up to 12.3 ng/mL. BPA was found in 95% of the samples, with concentrations up to 37.7 ng/mL.

Ideally, substitutes used to replace a chemical of concern would be inert, or at least far less toxic than the original chemical(s). Unfortunately, many chemical replacements are untested before being placed on the market, and in some cases are similar enough to the original chemical to cause concern. For that reason, such chemical analogs should be evaluated before they are used as replacements for toxic chemicals. These chemicals may be just as harmful as the originals---or more so---and have been described as "regrettable substitutions," as is the case with several perfluorinated chemicals ([@r23]), pesticides ([@r11]), and flame retardants ([@r4]). In the case of BPS and BPF, these chemicals are structural analogs to BPA ([Figure 1](#f1){ref-type="fig"}); thus their effects in physiological systems may be similar. BPA is a known endocrine disruptor based on *in vitro* ([@r74]) and animal laboratory studies ([@r52]; [@r65]), and exposures to environmental levels of BPA have been associated with adverse health outcomes in children and adults in more than 75 human studies ([@r54]). To evaluate the endocrine-disrupting properties of the BPA substitutes BPS and BPF, we conducted a systematic review of the literature using the National Institute of Environmental Health Sciences' Office of Health Assessment and Translation (OHAT) systematic review protocol ([@r44]; [@r55]). In this analysis we summarize *in vivo* and *in vitro* literature and compare the hormonal potency of BPS and BPF to BPA using the *in vitro* studies.
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*Literature search and review*. We performed a comprehensive literature search in order to identify studies describing endocrine and other physiological effects of exposure to BPF and BPS. The search included all articles published and indexed for all years to June 2014. Electronic searches were performed in Web of Science (<https://webofknowledge.com/>) and PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) using CAS registry numbers and common names. Our search logic is summarized in [Table 1](#t1){ref-type="table"}.

###### 

BPS and BPF search logic.

        PubMed and Web of Science search logic
  ----- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BPF   620-92-8\[EC/RN\] OR bisphenol-F OR (bisphenol\* AND BPF) OR bis(4-hydroxyphenyl)methane OR bis(p-hydroxyphenyl)methane OR bis(4-hydroxyphenyl)-methane OR bis(p-hydroxyphenyl)-methane OR p-(p-hydroxybenzyl)phenol OR p-(p-hydroxybenzyl)-phenol OR 4-(4-hydroxybenzyl)phenol OR 4-(4-hydroxybenzyl)-phenol OR "4,4'-methylenebis(phenol)" OR "p,p'-bis(hydroxyphenyl)methane" OR "p,p'-bis(hydroxyphenyl)-methane" OR "4,4'-bis(hydroxyphenyl)methane" OR "4,4'-bis(hydroxyphenyl)-methane" OR "4,4'-dihydroxydiphenylmethane" OR "4,4'-dihydroxydiphenyl-methane" OR "4,4'-methylenediphenol" OR "4,4'-methylene-diphenol" OR "4,4'-methylenebisphenol" OR "4,4'-methylene-bisphenol"
  BPS   80-09-1\[EC/RN\] OR bisphenol-S OR \[(bisphenol OR bisphenols) AND BPS\] OR bis(4-hydroxyphenyl)-sulfone OR bis(4-hydroxyphenyl)sulfone OR bis(4-hydroxyphenyl)-sulphone OR bis(4-hydroxyphenyl)sulphone OR bis(p-hydroxyphenyl)-sulfone OR bis(p-hydroxyphenyl)sulfone OR bis(p-hydroxyphenyl)-sulphone OR bis(phydroxyphenyl)sulphone OR 4,4'-dihydroxydiphenyl-sulfone OR 4,4'-dihydroxydiphenylsulfone OR 4,4'-dihydroxydiphenyl-sulphone OR 4,4'-dihydroxydiphenylsulphone OR p,p'-dihydroxydiphenyl-sulfone OR p,p'-dihydroxydiphenylsulfone OR p,p'-dihydroxydiphenyl-sulphone OR p,p'-dihydroxydiphenylsulphone OR 4,4'-sulfonyldiphenol OR 4,4'-sulfphonyldiphenol OR p,p'-sulfonyldiphenol OR p,p-sulfphonyldiphenol OR 4,4'-sulfonylbisphenol OR 4,4'-sulfphonylbisphenol OR p,p'-sulfonylbisphenol OR p,p-sulfphonylbisphenol OR 4,4'-sulfonylbiphenol OR 4,4'-sulfphonylbiphenol OR p,p'-sulfonylbiphenol OR p,p'-sulfphonylbiphenol OR 4-hydroxyphenyl-sulfone OR 4-hydroxyphenylsulfone OR 4-hydroxyphenyl-sulphone OR 4-hydroxyphenylsulphone OR p-hydroxyphenyl-sulfone OR p-hydroxyphenylsulfone OR p-hydroxyphenyl-sulphone OR p-hydroxyphenylsulphone

For inclusion, the studies had to be primary literature and assess any *in vitro* or *in vivo* physiological effects of BPS or BPF exposure. Two independent reviewers (J.R.R. and A.L.B.) screened all titles and abstracts for relevancy, using Distiller SR® software (Evidence Partners), and resolved any conflicts or discrepancies. Data from the studies were extracted, and were cross-checked by the two reviewers. When needed, data were extracted from figures or graphs using Universal Desktop Ruler® software (version 3.6; AVPSoft), with measurements taken in triplicate by a single reviewer.

Study quality for *in vivo* studies was assessed using a protocol developed by OHAT. Briefly, risk of bias (RoB) in experimental methodology was assessed by answering 14 questions. The RoB questions covered biases in subject selection, protocol performance, attrition/exclusion of subjects, detection of outcomes, selective reporting of outcomes, and statistical methodology. Questions were rated as "definitely low RoB," "probably low RoB," "probably high RoB," or "definitely high RoB" depending on standardized responses. The individual RoB questions are provided in [Figure 2](#f2){ref-type="fig"}. Next, "key" study quality questions, identified *a priori*, were used to determine the initial quality of each study, then ratings of the remaining questions were used to determine the overall study quality: "low," "moderate," or "high." If any study received a "low" rating, it was removed from analysis. This protocol has been described in detail elsewhere ([@r44]; [@r55]).

![Risk of bias (RoB) ratings for BPS and BPF *in vivo* studies. Abbreviations: ^++^, definitely low risk of bias; ^+^, probably low risk of bias; --, probably high risk of bias; NA, not applicable.](ehp.1408989.g002){#f2}

As specified in the OHAT protocol ([@r44]; [@r55]), *in vitro* studies were not assessed for quality, but were used to support specific *in vivo* end points. For example, estrogen receptor (ER) binding or activation studies support the biological plausibility of increased uterine growth, an *in vivo* estrogenic response. Where there were at least three *in vitro* studies, the strength of support was rated on the following factors: relevance of biological process or pathway to human disease, consistency across model systems (where there were more than two systems), physiological relevance of the dose concentration, potency (magnitude of response compared with positive control), dose response (monotonic or nonmonotonic), and publication bias. These factors were integrated for a final rating of "weak," "moderate," or "strong" *in vitro* support of the biological plausibility of *in vivo* observations, but they were not used to exclude studies. *In vitro* observations that had fewer than three studies per end point, or did not relate to any observed *in vivo* end points, are described in the text.

Results
=======

Our search identified 1,370 studies; of these, 32 studies (25 *in vitro* only and 7 *in vivo*) were identified as relevant for inclusion. [Figure 2](#f2){ref-type="fig"} shows the study quality ratings for the *in vivo* studies. All studies were rated moderate quality or better; therefore, no *in vivo* studies were removed because of low quality.

*BPS*. The literature reporting the physiological effects of BPS exposure consisted of 4 *in vivo* studies and 18 *in vitro* studies. The *in vivo* studies are presented in [Table 2](#t2){ref-type="table"}. BPS exposure caused acute toxicity in *Daphnia magna* ([@r9]). [@r75] found that postnatal BPS exposure in rats caused an induction of uterine growth, a marker of estrogen exposure ([@r47]), at the lowest and highest doses. The authors also found that BPS bound to the nuclear ER at 0.0055% relative binding affinity ([@r75]). [@r24] studied BPS exposure in zebrafish (*Danio rerio*) and found decreases in gonad weight, alterations in plasma estrogen and testosterone, and disrupted reproduction (i.e., decreased egg production and hatchability, increased time to hatch, increased embryo malformations). Another study in zebrafish showed that BPS exposure increased female to male sex ratio; decreased body length; altered testosterone, estradiol, and vitellogenin concentrations; and led to reproductive disruption (i.e., decreased egg production, increased time to hatch, decreased sperm count) ([@r42]).

###### 

*In vivo* BPS and BPF hormonal/physiological effect studies.

  Chemical                                                                                                                                                                                                                                                     Study                     Model             Exposure duration   Age at exposure   Route of exposure   Doses                           LOEL^*a*^   Results
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------- ----------------- ------------------- ----------------- ------------------- ------------------------------- ----------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BPS                                                                                                                                                                                                                                                          Chen et al. 2002          *Daphnia magna*   2 or 4 days         Juvenile          Culture             NA                              NA          BPS was acutely toxic in *Daphnia magna;* EC~50~, 76 mg/L (24 hr); EC~50~ 55 mg/L (48 hr). BPS showed estrogenic activity and did not show mutagenic activity *in vitro*.
  BPS                                                                                                                                                                                                                                                          Yamasaki et al. 2004      Rat               3 days              20 days           Injection           0, 20, 100, 500 mg/kg/day       20 mg/kg    BPS exposure was estrogenic in rats via increases in uterine weight. BPS was also found to bind the estrogen receptor.
  BPS                                                                                                                                                                                                                                                          Ji et al. 2013            *Danio rerio*     21 days             3--5 months       Water               0, 0.5, 5, 50 μg/L              0.5 μg/L    BPS exposure in zebrafish showed decreases in gonad weight with respect to body weight in males and females. No changes were observed in liver or brain weight with respect to body weight. E~2~ levels were increased in males and in females, T levels were decreased in males, and E~2~/T ratios were increased in males and females. Reproduction was impaired as evidenced by decreased egg production and hatchability, and by increased time to hatch and embryo malformation rates. Gene expression in the brain and gonads of several genes involved in the hypothalamic--pituitary--gonadal axis were altered in males and females.
  BPS                                                                                                                                                                                                                                                          Naderi et al. 2014        *Danio rerio*     75 days             4--6 months       Water               0, 0.1, 1, 10, 100 μg/L         1 μg/L      BPS exposure in zebrafish showed decreased body length and weight in males, increased female to male sex ratio, decreased gonad weight, increased liver weight, decreased T~3~ and T~4~, decreased T in males, increased E~2~ in males and females, and increased VTG in males and females. BPS also caused disrupted reproduction, with decreased number of eggs produced, decreased hatching rate, increased time to hatch, and decreased sperm count.
  BPF                                                                                                                                                                                                                                                          Chen et al. 2002          *Daphnia magna*   2 or 4 days         Juvenile          Culture             NA                              NA          EC~50~, 80 mg/L (24 hr); and EC~50~ 56 mg/L (48 hr). BPF showed estrogenic activity and did not show mutagenic activity *in vitro*.
  BPF                                                                                                                                                                                                                                                          Yamasaki et al. 2003      Rat               10 days             19 days           Gavage              0, 50, 200, 1,000 mg/kg/day     100 mg/kg   BPF co-administered with TP increased the weight of the Cowper's gland. BPF alone and combined with TP decreased body weight.
  BPF                                                                                                                                                                                                                                                          Yamasaki et al. 2004      Rat               3 days              20 days           Injection           0, 100, 300, 1,000 mg/kg/day    100 mg/kg   BPF induced uterine growth in immature rats. BPF was positive for relative binding affinity (E~2~).
  BPF                                                                                                                                                                                                                                                          Higashihara et al. 2007   Rat               28 days             8 weeks           Gavage              0, 20, 100, 500 mg/kg/day       20 mg/kg    There were decreases in body weight and food consumption in males and females treated with BPF. Hematological and biochemical parameters were altered, including decreased cholesterol and glucose in males and females. BPF treatment decreased T~3~ and increased T~4~ levels. BPF increased testes, liver, thyroid, brain, and kidney weights.
  BPF                                                                                                                                                                                                                                                          Stroheker et al. 2003     Rat               4 days              22 days           Gavage              0, 25, 50, 100, 200 mg/kg/day   100 mg/kg   BPF was shown to increase uterine weight in rats.
  Abbreviations: EC~50~, half-maximal effective concentration; NA, not available; T, testosterone; T~3~, triiodothyronine; T~4~, thyroxin; TP, testosterone propionate; VTG, vitellogenin. ^***a***^The dose at the end point of the lowest observed effect.                                                                                                                                                     

*In vitro* data from 12 studies assessing estrogenicity provided strong evidence supporting the estrogenic responses observed in *in vivo* studies ([Table 3](#t3){ref-type="table"}), based on relevance of the end point to human health \[e.g., interaction with human ERα and G-protein coupled receptor 30 (GPR30)\], consistent response across eight cell lines, and physiologically relevant concentrations assessed (micromolar range) ([@r9]; [@r19]; [@r21]; [@r20]; [@r28]; [@r29]; [@r39]; [@r51]; [@r56]; [@r63]; [@r71], [@r72]). Several of these studies showed that BPS had weaker estrogenic potency than estradiol (E~2~) when assayed in nuclear receptor models ([@r9]; [@r19]; [@r21]; [@r20]; [@r28]; [@r29]; [@r39]; [@r63]). However, two studies ([@r71], [@r72]) showed that BPS had equivalent or greater estrogenic potency to E~2~ when assayed in membrane receptor models; BPS induced membrane receptor--mediated pathways typically up-regulated by E~2~. Four studies showed that BPS bound to the ER in competitive binding assays ([@r19]; [@r20]; [@r39]; [@r75]). There was also one study showing androgenic activity of BPS ([@r39]) and one study showing antiandrogenic activity ([@r28]). In addition, in other *in vitro* experiments BPS exposure induced caspase 8 production, which indicates that BPS may alter cellular apoptotic and survival signaling ([@r57]; [@r71], [@r72]). BPS also had effects on hepatic cells ([@r49]); it bound to serum albumins ([@r37]), and it caused DNA damage ([@r15]; [@r21]; [@r31]).

###### 

Studies assessing BPS and BPF activity *in vitro*.

  Study                             Chemical(s) tested   End point measured                                                          Concentrations tested
  --------------------------------- -------------------- --------------------------------------------------------------------------- -----------------------------------------------------
  Audebert et al. 2011              BPF                  Cytotoxicity, genotoxicity                                                  1 to 100 μM
  Cabaton et al. 2006               BPF/BPS              Antiandrogenicity, estrogenicity, genotoxicity                              10^--11^ to 10^--5^ M and 36.4 to 170 μM
  Chen et al. 2002                  BPF/BPS              Acute toxicity, estrogenicity                                               0.01 to 100 mg/L
  Fic et al. 2013                   BPF/BPS              Cytotoxicity, genotoxicity, mutagenicity                                    12.5 to 100 μM, 0.1 to 10 μM, and 4 to 500 μg/plate
  Grignard et al. 2012              BPS                  Estrogenicity                                                               10^--12^ to 10^--4^ M
  Hashimoto and Nakamura 2000       BPF/BPS              Estrogenicity                                                               10^--7^ to 10^--3^ M
  Hashimoto et al. 2001             BPF/BPS              Estrogenicity                                                               10^--9^ to 10^--3^ M
  Kidani et al. 2010                BPF                  Adiponectin                                                                 80 μM
  Kitamura et al. 2003              BPF                  Estrogenic, estrogen CBA                                                    10^--8^ to 10^--4^ M
  Kitamura et al. 2005              BPF/BPS              Antiandrogenicity, estrogenicity                                            10^--7^ to 10^--4^ M
  Kuruto-Niwa et al. 2005           BPS                  Estrogenicity                                                               10^--7^ to 10^--4^ M
  Lee et al. 2013                   BPF/BPS              Cytotoxicity, genotoxicity                                                  10 to 250 μM
  Mathew et al. 2014                BPS                  Serum albumin binding                                                       0.2 to 4 μM
  Molina-Molina et al. 2013         BPF/BPS              Androgenicity, antiandrogenicity, estrogenicity, estrogen CBA               10^--8^ to 10^--5^ M
  Nakagawa and Tayama 2000          BPF                  Cytotoxicity, mitochondrial function                                        0.25 to 1 mM
  Ogawa et al. 2006                 BPF                  Estrogenicity                                                               10^--7^ to 10^--3^ M
  Perez et al. 1998                 BPF                  Estrogenicity                                                               10^--8^ to 10^--5^ M
  Peyre et al. 2014                 BPS                  Hepatic cell function                                                       1 to 500 μM
  Pisapia et al. 2012               BPF                  Estrogenicity                                                               10^--7^ to 10^--5^ M
  Rajasärkkä et al. 2014            BPF/BPS              BPA activity, estrogenicity                                                 10^--7^ to 10^--2^ M
  Rosenmai et al. 2014              BPF/BPS              Antiandrogenicity, estrogenicity, steroidogenesis, AhR activity             10^--4^ to 10^2^ μM
  Satoh et al. 2004                 BPF                  Antiandrogenicity, cytotoxicity, estrogenicity, estrogen and androgen CBA   10^--9^ to 10^--3^ M
  Stroheker et al. 2004             BPF                  Antiandrogenicity, antiestrogenicity, estrogenicity, estrogen CBA           10^--10^ to 10^--5^ M
  Teng et al. 2013                  BPS                  Androgenicity, estrogenicity                                                10^--13^ to 10^--4^ M
  Viñas and Watson 2013a            BPS                  Estrogenicity                                                               10^--15^ to 10^--7^ M
  Viñas and Watson 2013b            BPS                  Estrogenicity                                                               10^--14^ M
  Yamasaki et al. 2004              BPS                  Estrogen CBA                                                                10^--11^ to 10^--4^ M
  CBA, competitive binding assay.                                                                                                    

*BPF*. Of the five *in vivo* studies, four showed that BPF was estrogenic, androgenic, and thyroidogenic ([Table 2](#t2){ref-type="table"}). Nineteen *in vitro* studies showed estrogenic, androgenic, and other physiological/biochemical effects ([Table 3](#t3){ref-type="table"}). BPF was acutely toxic in *Daphnia magna* ([@r9]). Two studies showed that BPF exposure induced uterine growth in rats, indicating estrogenic activity ([@r61]; [@r75]). There were also two studies that showed evidence of androgenic activity: One study indicated that BPF increased the weight of the testes ([@r22]), and the other showed a cumulative effect of BPF when co-administered with testosterone propionate that increased Cowper's gland weight ([@r76]). The cumulative effect indicates that BPF may augment other androgens, if indeed it acts synergistically. BPF exposure also increased thyroid weight and altered thyroid hormone concentrations, as well as caused changes to hematological parameters and enzyme expression ([@r22]).

As shown in [Table 3](#t3){ref-type="table"}, *in vitro* data from 12 studies provided strong evidence that BPF had estrogenic activity, supporting *in vivo* observations. This rating was based on relevance to human health (MCF-7 cell and human ER), consistency across five cell models, and the use of relevant concentrations (micromolar range) ([@r7]; [@r9]; [@r21]; [@r20]; [@r27], [@r28]; [@r39]; [@r48]; [@r50]; [@r51]; [@r56]; [@r58]). One study showed that BPF was not estrogenic in a yeast two-hybrid assay ([@r46]). One study indicated that BPF was antiestrogenic ([@r62]). Moderate evidence from 6 studies showed that BPF was antiandrogenic based on relevance to human health \[i.e., human androgen receptor (AR)\], consistency across four cell models, and potency (i.e., within 100 orders of magnitude of positive control) ([@r7]; [@r28]; [@r39]; [@r56]; [@r58]; [@r62]). BPF also showed other *in vitro* effects such as cytotoxicity, cellular dysfunction, DNA damage, and chromosomal aberrations ([@r3]; [@r7]; [@r31]; [@r43]; [@r50]), and decreased adiponectin production and secretion *in vitro* ([@r26]).

*Potency of BPS and BPF compared with BPA*. BPS and BPF are already being used as alternatives for BPA; thus, it is important to understand whether these substitutes possess endocrine-disruptive/active properties similar to those of BPA. Seventeen studies tested BPS and/or BPF along with BPA in the same assays, allowing the potencies and mechanisms of action to be directly compared. [Table 4](#t4){ref-type="table"} presents these results, comparing the hormonal potencies of BPF and/or BPS to BPA. The average estrogenic potency (mean ± SD) for BPF compared with BPA was 1.07 ± 1.20, with a range of 0.10--4.83. The average estrogenic potency for BPS compared with BPA was 0.32 ± 0.28, with a range of 0.01--0.90. These results indicate that the potencies of BPS and BPF are in the same order of magnitude as the potency of BPA, and BPF may be just as potent (or more potent) than BPA. Further, BPS and BPF have potencies in the same order of magnitude as BPA in regard to androgenic, antiandrogenic, antiestrogenic, and aryl hydrocarbon activity and inhibitory hormonal signaling in adipocytes ([Table 4](#t4){ref-type="table"}).

###### 

*In vitro* BPS and BPF hormonal activity compared with BPA.

  Assay (receptor tested)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Chemical potency vs. positive control (control)   BPA potency vs. positive control (control)   Chemical potency compared with BPA potency^*a*^   Reference
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------- ------------------------------------------------- -----------------------------
  BPS, estrogenic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  MCF-7 GFP (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         5.54 × 10^--6^ (E~2~)                             8.86 × 10^--6^ (E~2~)                        0.62                                              Kuruto-Niwa et al. 2005
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NA (E~2~)                                         NA (E~2~)                                    0.67                                              Hashimoto and Nakamura 2000
  Yeast 2-hybrid (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    4.33 × 10^--6^ (E~2~)                             2.76 × 10^--5^ (E~2~)                        0.16                                              Hashimoto and Nakamura 2000
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NA (E~2~)                                         NA (E~2~)                                    0.90                                              Hashimoto et al. 2001
  Yeast 2-hybrid (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    4.83 × 10^--6^ (E~2~)                             2.40 × 10^--5^ (E~2~)                        0.20                                              Hashimoto et al. 2001
  Yeast 2-hybrid (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    NC (E~2~)                                         NC (E~2~)                                    0.10                                              Chen et al. 2002
  MCF-7 luc (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         7.82 × 10^--6^ (E~2~)                             1.37 × 10^--5^ (E~2~)                        0.57                                              Kitamura et al. 2005
  MELN (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              9.76 × 10^--6^ (E~2~)                             1.77 × 10^--5^ (E~2~)                        0.55                                              Grignard et al. 2012
  BG1Luc4E2 (ERα, ERβ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    2.52 × 10^--7^ (E~2~)                             3.14 × 10^--6^ (E~2~)                        0.08                                              Grignard et al. 2012
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1.0 × 10^--6^ (E~2~)                              3.75 × 10^--5^ (E~2~)                        0.03                                              Molina-Molina et al. 2013
  MELN (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NR                                                NR                                           0.04                                              Molina-Molina et al. 2013
  HELN (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NR                                                NR                                           0.10                                              Molina-Molina et al. 2013
  HELN (ERβ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NR                                                NR                                           0.30                                              Molina-Molina et al. 2013
  CV-1 luc (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          5.73 × 10^--5^ (E~2~)                             4.63× 10^--4^ (E~2~)                         0.12                                              Teng et al. 2013
  GH3/B6/F10 ERK (mER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    0.68 (E~2~)                                       1.56 (E~2~)                                  0.43                                              Viñas and Watson 2013a
  GH3/B6/F10 ERK (mER)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1.36 (E~2~)                                       1.91 (E~2~)                                  0.71                                              Viñas and Watson 2013b
  Yeast bioreporter (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 NR                                                NR                                           0.01                                              Rajasärkkä et al. 2014
  BG1Luc4E2 (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NC (E~2~)                                         NC (E~2~)                                    0.23                                              Rosenmai et al. 2014
  BPS average estrogenic potency compared with BPA (mean ± SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0.32 ± 0.28                                       
  BPS, antiandrogenic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  NIH353 + DHT (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.18 (Flutamide)                                  0.58 (Flutamide)                             0.25                                              Kitamura et al. 2005
  BPS, androgenic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  MCF-7 AR1 (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          9.00 × 10^--7^ (R1881)                            2.25 × 10^--6^ (R1881)                       0.40                                              Molina-Molina et al. 2013
  PALM (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               NR                                                NR                                           0.79                                              Molina-Molina et al. 2013
  BPS, BPA activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Yeast bioreporter (BPAR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                2.50 × 10^--2^ (BPA)                              1.00 (BPA)                                   0.03                                              Rajasärkkä et al. 2014
  BPF, estrogenic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1.0 × 10^--3^ (E~2~)                              0.01 (E~2~)                                  0.10                                              Perez et al. 1998
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NA (E~2~)                                         NA (E~2~)                                    0.89                                              Hashimoto and Nakamura 2000
  Yeast 2-hybrid (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    6.69 × 10^--6^ (E~2~)                             2.76 × 10^--5^ (E~2~)                        2.42                                              Hashimoto and Nakamura 2000
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          NA (E~2~)                                         NA (E~2~)                                    0.99                                              Hashimoto et al. 2001
  Yeast 2-hybrid (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    6.39 × 10^--5^ (E~2~)                             2.40 × 10^--5^ (E~2~)                        2.67                                              Hashimoto et al. 2001
  Yeast 2-hybrid (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    NC (E~2~)                                         NC (E~2~)                                    0.79                                              Chen et al. 2002
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          5.31 × 10^--5^ (E~2~)                             1.10 × 10^--5^ (E~2~)                        4.83                                              Stroheker et al. 2004
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          4.67 × 10^--6^ (E~2~)                             7.78 × 10^--6^ (E~2~)                        0.60                                              Satoh et al. 2004
  MVLN luc (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          5.86 × 10^--6^ (E~2~)                             1.17 × 10^--5^ (E~2~)                        0.50                                              Satoh et al. 2004
  MCF-7 luc (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         8.6 × 10^--6^ (E~2~)                              1.37 × 10^--5^ (E~2~)                        0.63                                              Kitamura et al. 2005
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          0.55 (E~2~)                                       0.86 (E~2~)                                  0.64                                              Pisapia et al. 2012
  E-screen (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          1.0 × 10^--5^ (E~2~)                              3.75 × 10^--5^ (E~2~)                        0.27                                              Rajasärkkä et al. 2014
  MELN (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NR                                                NR                                           0.48                                              Molina-Molina et al. 2013
  HELN (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NR                                                NR                                           0.29                                              Molina-Molina et al. 2013
  HELN (ERβ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              NR                                                NR                                           0.36                                              Molina-Molina et al. 2013
  Yeast bioreporter (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 NR                                                NR                                           1                                                 Rajasärkkä et al. 2014
  BG1Luc4E2 (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         NC (E~2~)                                         NC (E~2~)                                    0.81                                              Rosenmai et al. 2014
  BPF average estrogenic potency compared with BPA (mean ± SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           1.07 ± 1.20                                       
  BPF, antiandrogenic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  MDA-MB453+DHT (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      NR                                                NR                                           0.78                                              Stroheker et al. 2004
  AR-EcoScreen+DHT (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   0.03 (Cyproterone acetate)                        0.06 (Cyproterone acetate)                   0.52                                              Satoh et al. 2004
  NIH353+DHT (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         0.21 (Flutamide)                                  0.58 (Flutamide)                             0.36                                              Kitamura et al. 2005
  PALM (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               NR                                                NR                                           0.13                                              Molina-Molina et al. 2013
  CHO AR (AR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             NC (R1881)                                        NC (R1881)                                   0.94                                              Rosenmai et al. 2014
  BPF average antiandrogenic potency compared with BPA (mean ± SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.55 ± 0.32                                       
  BPF, antiestrogenic activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  E-screen+tamoxifin (ERα)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                NR                                                NR                                           1.12                                              Stroheker et al. 2004
  BPF, adiponectin secretion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  3T3-L1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  NR                                                NR                                           0.56                                              Kidani et al. 2010
  BPF, BPA activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Yeast bioreporter (BPAR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                2.50 × 10^--3^ (BPA)                              1.00 (BPA)                                   0.003                                             Rajasärkkä et al. 2014
  BPF, AhR activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  H4IIE/CALUX (AhR)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       NC (TCDD)                                         NC (TCDD)                                    1.2                                               Rosenmai et al. 2014
  Abbreviations: AhR, aryl hydrocarbon receptor; AR, androgen receptor; BPAR, BPA-targeted receptor; DHT, dihydrotestosterone; GFP, green fluorescent protein; luc, luciferase; mER, membrane estrogen receptor; NA, not available; NC, not able to calculate from the data presented (e.g., the positive control values were not reported); NR, not reported; TCDD, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin. ^***a***^Potencies were calculated by dividing the BPS or BPF potency by the BPA potency in the same study.                                                                                                                                                    

[@r56] used several assays to assess steroidogenic activity, as well as teratogenicity, genotoxicity, carcinogenicity, and metabolic effects. Similar to the present evaluation, they found that BPS and BPF had estrogen receptor binding, estrogenic activity, and antiandrogenic activity similar to those of BPA, with BPS being the least potent. However, BPS and BPF exhibited the greatest steroidogenic (i.e., progesterone) activity, increasing levels of 17α-hydroxyprogesterone and progesterone levels, whereas BPA did not ([@r56]). Although the authors did not examine the mechanism of action of progesterone up-regulation, previous work suggested a direct inhibition of the CYP17 (cytochrome P450 17A1) lyase reaction, independent of ER action ([@r78]). Thus, BPA analogs may have additional disruptive effects that have not been detected with BPA.

Discussion
==========

Although relatively few studies have examined the hormonal actions of BPS and BPF (especially *in vivo*), the *in vitro* literature indicates that BPS and BPF have actions and potencies similar to those of BPA and supports the biological plausibility of their hormonal activity *in vivo.* This is not surprising because BPF and BPS are structural analogs of BPA and thus mechanisms of action would be expected to be similar. For example, BPF showed cumulative, possibly synergistic, actions *in vivo* when co-administered with an androgen ([@r76]), and BPA has also been shown to have these types of effects when combined with other hormones or xenoestrogens ([@r25]; [@r59]). Particularly interesting is the fact that BPS seems to have actions on nongenomic signaling similar to those of BPA ([@r71], [@r72]). BPA is sometimes called a "weak" estrogen because of its relatively weak binding/activation of the nuclear receptors compared with E~2~, although this is not always the case ([Table 3](#t3){ref-type="table"}; [@r28]; [@r48]; [@r50]). However, when the nongenomic estrogenic activity of BPA was measured, it was comparable, if not more potent, than E~2~. This potent, nongenomic estrogenic activity of BPA has been described in several experimental models ([@r1], [@r2]; [@r71], [@r72]; [@r73]). The potency of BPS in a nongenomic signaling assay was similar to that of BPA. In femtomolar to picomolar concentrations, BPS induced membrane ERα-mediated pathways and actions: MAPK (mitogen-activated protein kinase) signaling, cell proliferation, and activation of caspase 8 ([@r71], [@r72]). These rapid, nongenomic pathways are important for optimal cell function, mediating proliferation and apoptosis ([@r71], [@r72]), as well as other actions such as pancreatic cell function ([@r1]) and estrogen-mediated brain function and behavior ([@r30]; [@r38]).

BPS and BPF had potencies in the same order of magnitude as BPA. The issue of potency is complicated because of the fact that lowest observed effect levels depend on end point, receptor type, pathway, tissues, windows of exposure, and so on. In general, BPS was slightly less potent than BPA. The average BPF potency was similar to BPA, with a fairly wide range of potencies. However, the implications of these differences are not clear. In regard to potency, it is not known whether a compound that is, for example, half as potent as BPA *in vitro* would have half the effect *in vivo*, especially because very little is known about the exposure and metabolism of BPS and BPF. Further, even if potencies of BPS and BPF are slightly less than that of BPA, it is unclear if these compounds are safer; many scientists have advocated a "no-threshold" approach to endocrine disruption because thresholds may change during development or may be very difficult to assess ([@r40]).

The metabolism and biological fate of BPS and BPF have not been well studied, but *in vitro* and *in vivo* experiments indicated that BPF metabolism and distribution are similar to those of BPA. *In vitro,* BPA was metabolized by human and rat hepatic cells to many different metabolites, including non-bioactive sulfate and glucuronide conjugates ([@r8]; [@r14]). *In vivo*, BPF administered to pregnant rats via gavage resulted in the excretion of BPF and several metabolites in the urine, including the nonactive sulfate-conjugated BPF. Active BPF was also distributed to many tissues, including the uterus, placenta, amniotic fluid, and fetuses. The ratio of the active parent compound to the metabolites/conjugates was similar to that of BPA ([@r6]; [@r69]). The primary route of excretion for BPF appeared to be through the sulfatase conjugate, rather than the glucuronide conjugate (as with BPA). [@r6] suggested that this may be due to the fact that BPF glucuronide may be more easily deconjugated to its bioactive state and reabsorbed in large quantities, which also appears to occur with BPA ([@r69]). No studies have assessed the metabolism of BPS or the bioactivity of the metabolites. Studies determining the metabolism of BPS and the bioactivity of metabolites from BPF and BPS are warranted.

The body of literature on the *in vivo* effects of BPS and BPF is scant, but it points to these chemicals as endocrine disruptors and reproductive toxicants. BPS induced uterine growth in rodents (indicative of estrogenic action) and disrupted reproduction in fish ([@r24]; [@r42]; [@r75]), and BPF also had uterotropic (estrogenic) effects in female rodents and gonadotropic (androgenic) effects in male rodents ([@r22]; [@r61], [@r62]; [@r75]). Although most of the *in vitro* data support estrogenic, and to some extent, antiandrogenic, actions of BPS and BPF ([Table 3](#t3){ref-type="table"}), one *in vitro* study showed that BPS has androgenic activity similar to BPA ([@r39]). Thus, the *in vitro* data support the *in vivo* observations of hormonal and endocrine disruptive activity of these compounds.

Concern over the endocrine-disruptive effects of BPA has resulted in hundreds of laboratory studies, including *in vitro* ([@r74]) and *in vivo* ([@r53]; [@r65]) studies, identifying estrogenic and other effects. Although some regulators have rejected this body of literature because of a lack of standardized protocols, reviews of these studies have indicated strong methodologies and stringent laboratory practices, often of higher quality than studies employing Good Laboratory Practices ([@r41]). Many *in vivo* BPA studies have demonstrated adverse outcomes at "low" (i.e., environmentally or physiologically relevant) doses ([@r64]; [@r67]). Many studies also report that BPA has a nonlinear, or nonmonotonic, dose--response curve. Nonmonotonic dose responses are indicative of an endocrine-mediated response and are consistent with natural hormone responses ([@r65]; [@r67], [@r68]; [@r80]). Further, nearly 100 human studies described the relationship between BPA and several endocrine-related health impacts on reproduction, neurodevelopment, thyroid function, and metabolic health ([@r54]). Although epidemiological studies are less controlled than laboratory animal experiments, making it difficult to show causation, they are important indicators of potential health effects ([@r13]; [@r80]). Further, although BPA is quickly metabolized and excreted from the body \[with a half life of about 6 hr ([@r12])\], the fact that it is found in almost all humans sampled at any one time suggests the ubiquitous and constant nature of BPA exposure ([@r66]), which is disconcerting in light of the animal and human evidence of health effects. Many researchers have raised concern over this overwhelming evidence and have called for stricter regulation of BPA ([@r70], [@r67]). Although this concern has prompted BPA to be phased out of certain products ([@r17]), the structural analog replacements may not be any safer.

Because BPS and BPF appear to have metabolism, potencies, and mechanisms of action *in vitro* similar to BPA, including hormonal actions beyond that of BPA, they may pose similar potential health hazards as BPA. Therefore, when evaluating the safety of compounds for consumer use, it may be prudent to consider entire classes instead of individual compounds. In addition, as other researchers have suggested ([@r71]), future research efforts should focus on designing chemical substitutes that do not have biological or hormonal activity similar to those of BPA. Further, this review demonstrates that systematic reviews may be useful in the process of conducting safety evaluations of chemical classes. The use of the bisphenol class of compounds as replacements for BPA in consumer products with high human contact should be implemented with caution.
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